Management of Bone Disease and Body Composition Changes

  • Author: Donald P. Kotler, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 5/7/18 (What's New)


  • Tenofovir AF a novel prodrug of tenofovir that results in lower plasma concentrations and higher intracellular concentrations of tenofovir relative to tenofovir DF[Ruane 2013]
  • Tenofovir AF has superior antiviral efficacy through 144 weeks and reduced bone toxicity when compared with tenofovir DF[Sax 2015; Arribas 2017]

Action required